NASDAQ:COLL
Collegium Pharmaceutical Stock News
$32.47
-1.20 (-3.56%)
At Close: May 17, 2024
William Blair Remains a Buy on Revance Therapeutics (RVNC)
02:26pm, Friday, 27'th Mar 2020
In a report released today, Tim Lugo from William Blair maintained a Buy rating on Revance Therapeutics (RVNC). The company's shares closed last Monday at
William Blair Remains a Buy on Revance Therapeutics (RVNC)
02:26pm, Friday, 27'th Mar 2020
In a report released today,
Tim Lugo
from William Blair maintained a
Buy
rating on Revance Therapeutics (
RVNC
–
Research Report
). The company’s shares closed last Monday at $15.27.
According to
William Blair Maintains a Buy Rating on Biohaven Pharmaceutical Holding Co (BHVN)
02:26pm, Friday, 27'th Mar 2020
William Blair analyst Tim Lugo maintained a Buy rating on Biohaven Pharmaceutical Holding Co (BHVN) on March 23. The company's shares closed last Monday
William Blair Maintains a Buy Rating on Biohaven Pharmaceutical Holding Co (BHVN)
02:26pm, Friday, 27'th Mar 2020
William Blair analyst Tim Lugo maintained a Buy rating on Biohaven Pharmaceutical Holding Co (BHVN – Research Report) on March
Collegium Pharmaceutical (COLL) Receives a Buy from Needham
11:34am, Friday, 27'th Mar 2020
In a report released today, Serge Belanger from Needham maintained a Buy rating on Collegium Pharmaceutical (COLL), with a price target of $38.00. The
Collegium Pharmaceutical (COLL) Receives a Buy from Needham
11:34am, Friday, 27'th Mar 2020
In a report released today, Serge Belanger from Needham maintained a Buy rating on Collegium Pharmaceutical (COLL – Research Report),
Analysts Anticipate Collegium Pharmaceutical Inc (NASDAQ:COLL) Will Announce Earnings of $0.35 Per Share
07:32am, Friday, 27'th Mar 2020
Wall Street analysts expect Collegium Pharmaceutical Inc (NASDAQ:COLL) to announce $0.35 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Six analysts h
The Call On Collegium Pharmaceuticals
04:36pm, Thursday, 26'th Mar 2020
Today, we take an in-depth look at a 'Tier 3' biopharma concern named Collegium Pharmaceuticals. The shares were lifted over the past few months by increasingly
COLL or NBIX: Which Is the Better Value Stock Right Now?
03:40pm, Thursday, 26'th Mar 2020
COLL vs. NBIX: Which Stock Is the Better Value Option?
COLL or NBIX: Which Is the Better Value Stock Right Now?
03:40pm, Thursday, 26'th Mar 2020
COLL vs. NBIX: Which Stock Is the Better Value Option?
William Blair Maintains a Buy Rating on Allakos (ALLK)
10:46am, Thursday, 26'th Mar 2020
William Blair analyst Tim Lugo maintained a Buy rating on Allakos (ALLK) yesterday. The company's shares closed last Monday at $50.89. According to
William Blair Maintains a Buy Rating on Allakos (ALLK)
10:46am, Thursday, 26'th Mar 2020
William Blair analyst
Tim Lugo
maintained a
Buy
rating on Allakos (
ALLK
–
Research Report
) yesterday. The company’s shares closed last Monday at $50.89.
According to
TipRanks.com
, Lugo is a 2-s
Collegium Pharmaceutical (NASDAQ:COLL) Trading Up 17.1%
07:14am, Wednesday, 25'th Mar 2020
Collegium Pharmaceutical Inc (NASDAQ:COLL) shares were up 17.1% on Tuesday . The company traded as high as $16.49 and last traded at $16.28, approximately 537,119 shares traded hands during mid-day tr
Edited Transcript of COLL earnings conference call or presentation 27-Feb-20 9:30pm GMT
09:03am, Tuesday, 24'th Mar 2020
Q4 2019 Collegium Pharmaceutical Inc Earnings Call
Citigroup Inc. Purchases 6,588 Shares of Collegium Pharmaceutical Inc (NASDAQ:COLL)
09:08am, Monday, 23'rd Mar 2020
Citigroup Inc. boosted its position in Collegium Pharmaceutical Inc (NASDAQ:COLL) by 50.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 19,663 shares
